All In Biotech

Drug Trial Radar · NCT04400331

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

154

Actual

Start

Sep 18, 2020

Primary completion

Nov 5, 2025

Study completion Nov 5, 2025

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
Collaborators
Huntington Study Group
First posted
May 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to valbenazine for the treatment of chorea associated with Huntington disease.

Conditions

  • Chorea, Huntington

Interventions

  • ValbenazineDrug

    vesicular monoamine transporter 2 (VMAT2) inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 262 weeks

Locations

34 sites in 2 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Birmingham, Alabama

  • Neurocrine Clinical Site

    Little Rock, Arkansas

  • Neurocrine Clinical Site

    La Jolla, California

  • Neurocrine Clinical Site

    Aurora, Colorado

  • Neurocrine Clinical Site

    Washington D.C., District of Columbia

  • Neurocrine Clinical Site

    Boca Raton, Florida

  • Neurocrine Clinical Site

    Gainesville, Florida

  • Neurocrine Clinical Site

    Atlanta, Georgia

  • Neurocrine Clinical Site

    Chicago, Illinois

  • Neurocrine Clinical Site

    Chicago, Illinois

  • Neurocrine Clinical Site

    Indianapolis, Indiana

  • Neurocrine Clinical Site

    Iowa City, Iowa

  • Neurocrine Clinical Site

    Wichita, Kansas

  • Neurocrine Clinical Site

    Louisville, Kentucky

  • Neurocrine Clinical Site

    New Orleans, Louisiana

  • Neurocrine Clinical Site

    Boston, Massachusetts

  • Neurocrine Clinical Site

    Charlestown, Massachusetts

  • Neurocrine Clinical Site

    Ann Arbor, Michigan

  • Neurocrine Clinical Site

    Omaha, Nebraska

  • Neurocrine Clinical Site

    Rochester, New York

  • Neurocrine Clinical Site

    Williamsville, New York

  • Neurocrine Clinical Site

    Durham, North Carolina

  • Neurocrine Clinical Site

    Columbus, Ohio

  • Neurocrine Clinical Site

    Toledo, Ohio

  • Neurocrine Clinical Site

    Pittsburgh, Pennsylvania

  • Neurocrine Clinical Site

    Charleston, South Carolina

  • Neurocrine Clinical Site

    Columbia, South Carolina

  • Neurocrine Clinical Site

    Greenville, South Carolina

  • Neurocrine Clinical Site

    Nashville, Tennessee

  • Neurocrine Clinical Site

    Houston, Texas

  • Neurocrine Clinical Site

    Burlington, Vermont

  • Neurocrine Clinical Site

    Vancouver, British Columbia, Canada

  • Neurocrine Clinical Site

    Ottawa, Ontario, Canada

  • Neurocrine Clinical Site

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.